CTSA Program Posters

Learning healthcare (LHC) incorporates learning seamlessly into everyday patient care and is crucial to rapidly advancing patient outcomes and ultimately population health. Observational studies are valuable in generating new hypotheses and identifying highly effective therapies (resulting in a published relative risk for adverse outcome <0.10 compared to placebo or usual care). However, the great

Coronavirus disease 2019 (COVID-19) is a global pandemic. Although much has been learned about the novel coronavirus since its emergence, there are many open questions related to tracking its spread, describing symptomology, predicting the severity of infection, and forecasting healthcare utilization. Free-text clinical notes contain critical information for resolving these questions. Data-driven

When the COVID-19 pandemic hit in early 2020, traditional, in-person methods of community outreach and engagement (CE) had to be reimagined and redefined in order to accommodate new COVID-19 life-style and community needs. Through CE, the Oregon Clinical and Translational Research Institute (OCTRI) Community Research Hub works to connect and support researchers and community organizations (CBOs)

Introduction: The STOP COVID Trials were innovative fully-remote randomized controlled trials of fluvoxamine (a sigma1 receptor agonist with anti-inflammatory properties) vs placebo for treatment of outpatients with early COVID-19 who were self-isolating at home. Methods: The trials used eConsent and an electronic data capture system with integrated recruitment from the EPIC electronic health

UCLA CTSI Population Health Program Population health seeks to identify and address variation in needs, care experiences, intervention efficacy, and outcomes for a defined group. In health systems, closing gaps often require collective actions of complex interdependent medical and social care systems in communities. The CTSI co-developed a Population Health Program with the local health department

When the SARS-CoV-2 pandemic reached Colorado in early March 2020, the leadership team of the Colorado Clinical and Translational Sciences Institute (CCTSI) rapidly responded to this public health emergency by establishing a new rapid-review pilot grant program, the CCTSI COVID-19-Related Research Pilot Program (C2R2 Pilot) with $100,000 budgeted for this program. The goal of the C2R2 Pilot

The global pandemic caused by SARS-CoV-2 with the attendant morbidity and mortality requires urgent understanding of the natural course of COVID-19 and characterization of the factors of disease severity and poor outcomes. A significant source of data for COVID-19 research is patient data captured in electronic health records (EHRs). To leverage EHRs for COVID-19 research, the national Accrual to

Our work focuses on several gaps in clinical research training. First, trainees lack the early immersion in an environment where they learn that multi- and interdisciplinary science is the norm rather than the exception. This is because training often occurs at the graduate or post-graduate level and is focused on research methods and logistical and regulatory aspects of conducting clinical

The Institute for Translational Medicine (ITM) aims to make research breakthroughs happen and to put those discoveries into the real world to improve health. The ITM is a partnership between the University of Chicago and Rush in collaboration with Advocate Health Care, the Illinois Institute of Technology, Loyola University Chicago, and NorthShore University HealthSystem. The goal of the ITM

The Trial Innovation Network (TIN) is an established partnership with the CTSA Program, the National Center for Advancing Translational Science (NCATS), and other NIH Institutes and Centers. Currently (AUG 2019) the TIN is supporting 212 projects, including 134 active studies that represent 59 therapeutic areas. These projects create opportunities for the CTSA Program Hubs, the Trial Innovation